| Other commenters posted good responses IMHO. My statement wasn’t due to any particular incident or axe to grind. It’s my observation of groupthink among experts in both sciences and public policy. Specifically recently I was affected by shortages of stimulant medications for treatment of ADHD. These shortages appeared to be due to secret DEA limits. Generally Americans getting these medications are treated like suspects first and foremost, in part due to the DEAs pressure on pharmacies. Here’s one of the experts describing it: > The exact limit for each
> pharmacy is kept secret in
> order to prevent pharmacists
> from gaming the system,
> according to Krista Tongring,
> leader of the DEA compliance
> practice at Guidepost
> Solutions and a former agency
> attorney. Note the original problem to be solved was opioid overprescribing. Instead of solving that issue directly the DEA experts decided to restrict all controlled substances with murky limits for unclear reasons. Certainly not to help Americans with ADHD, narcolepsy, anxiety, or a host of other genuine and often debilitating conditions. The DEA’s only concern is “suspicious orders” and limiting the drugs. Hence a case of one set of experts being myopic in the face of the broader health care system in the US. https://fortune.com/2023/04/03/xanax-adderall-rules-patients... |